DPHARMA Stock Overview
Duopharma Biotech Berhad, an investment holding company, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally.
Duopharma Biotech Berhad Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||RM1.13|
|52 Week High||RM2.34|
|52 Week Low||RM1.06|
|1 Month Change||-23.65%|
|3 Month Change||-25.17%|
|1 Year Change||-50.76%|
|3 Year Change||9.98%|
|5 Year Change||60.53%|
|Change since IPO||180.23%|
Recent News & Updates
|DPHARMA||MY Pharmaceuticals||MY Market|
Return vs Industry: DPHARMA underperformed the MY Pharmaceuticals industry which returned -25.5% over the past year.
Return vs Market: DPHARMA underperformed the MY Market which returned -8.7% over the past year.
|DPHARMA Average Weekly Movement||4.6%|
|Pharmaceuticals Industry Average Movement||3.6%|
|Market Average Movement||5.5%|
|10% most volatile stocks in MY Market||11.5%|
|10% least volatile stocks in MY Market||2.9%|
Stable Share Price: DPHARMA is not significantly more volatile than the rest of MY stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: DPHARMA's weekly volatility (5%) has been stable over the past year.
About the Company
|1978||1,594||Leonard bin Abdul Shatar||https://duopharmabiotech.com|
Duopharma Biotech Berhad, an investment holding company, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers antacid, antiflatulant, antiulcerant, antidiarrhoeals, oral electrolyte replacers and anti-inflammatories, antiemietic and antinauseants, systematic antibacterials, antimycobacterials, anti-thrombotic, antihypertensives, antifungals, dermatological, emollients, lipid regulator/anti- antheroma, anaesthetics, psycholeptics, anti-epileptics, systematic antihistamines, opthalmologicals, otological, systemic corticosteroids drugs, and other therapeutic areas. It also provides mineral supplements, functional gastro-intestinal disorder drugs, vitamins, drugs used in diabetes, blood coagulation system, anti-thrombotic agent, renin-angiotensin system agent, lipid-antiotensin system agent, calcium antagonists, beta-blocking agent, cardiac therapy, diuretic, cerebral and peripheral vasotherapeutics, anti-rheumatic products, muscle relaxants, and anti-asthma and COPD products, as well as cough, cold, throat, and nasal preparations.
Duopharma Biotech Berhad Fundamentals Summary
|DPHARMA fundamental statistics|
Is DPHARMA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DPHARMA income statement (TTM)|
|Cost of Revenue||RM396.58m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.072|
|Net Profit Margin||10.38%|
How did DPHARMA perform over the long term?See historical performance and comparison
1.9%Current Dividend Yield
Is DPHARMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DPHARMA?
Other financial metrics that can be useful for relative valuation.
|What is DPHARMA's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does DPHARMA's PE Ratio compare to its peers?
|DPHARMA PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
AHEALTH Apex Healthcare Berhad
KOTRA Kotra Industries Berhad
YSPSAH Y.S.P. Southeast Asia Holding Berhad
RHONEMA Rhone Ma Holdings Berhad
DPHARMA Duopharma Biotech Berhad
Price-To-Earnings vs Peers: DPHARMA is expensive based on its Price-To-Earnings Ratio (15.7x) compared to the peer average (14.7x).
Price to Earnings Ratio vs Industry
How does DPHARMA's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: DPHARMA is expensive based on its Price-To-Earnings Ratio (15.7x) compared to the MY Pharmaceuticals industry average (13.9x)
Price to Earnings Ratio vs Fair Ratio
What is DPHARMA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||15.7x|
|Fair PE Ratio||22.4x|
Price-To-Earnings vs Fair Ratio: DPHARMA is good value based on its Price-To-Earnings Ratio (15.7x) compared to the estimated Fair Price-To-Earnings Ratio (22.4x).
Share Price vs Fair Value
What is the Fair Price of DPHARMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: DPHARMA (MYR1.13) is trading below our estimate of fair value (MYR1.46)
Significantly Below Fair Value: DPHARMA is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: DPHARMA is poor value based on its PEG Ratio (2x)
Discover undervalued companies
How is Duopharma Biotech Berhad forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DPHARMA's forecast earnings growth (7.8% per year) is above the savings rate (3.6%).
Earnings vs Market: DPHARMA's earnings (7.8% per year) are forecast to grow slower than the MY market (9.9% per year).
High Growth Earnings: DPHARMA's earnings are forecast to grow, but not significantly.
Revenue vs Market: DPHARMA's revenue (7.1% per year) is forecast to grow faster than the MY market (5.2% per year).
High Growth Revenue: DPHARMA's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DPHARMA's Return on Equity is forecast to be low in 3 years time (12.2%).
Discover growth companies
How has Duopharma Biotech Berhad performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DPHARMA has high quality earnings.
Growing Profit Margin: DPHARMA's current net profit margins (10.4%) are lower than last year (10.8%).
Past Earnings Growth Analysis
Earnings Trend: DPHARMA's earnings have grown by 12.9% per year over the past 5 years.
Accelerating Growth: DPHARMA's earnings growth over the past year (9.1%) is below its 5-year average (12.9% per year).
Earnings vs Industry: DPHARMA earnings growth over the past year (9.1%) underperformed the Pharmaceuticals industry 21.4%.
Return on Equity
High ROE: DPHARMA's Return on Equity (10.8%) is considered low.
Discover strong past performing companies
How is Duopharma Biotech Berhad's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: DPHARMA's short term assets (MYR526.3M) exceed its short term liabilities (MYR240.7M).
Long Term Liabilities: DPHARMA's short term assets (MYR526.3M) exceed its long term liabilities (MYR327.8M).
Debt to Equity History and Analysis
Debt Level: DPHARMA's net debt to equity ratio (41.9%) is considered high.
Reducing Debt: DPHARMA's debt to equity ratio has increased from 27.3% to 65.9% over the past 5 years.
Debt Coverage: DPHARMA's debt is not well covered by operating cash flow (15.4%).
Interest Coverage: DPHARMA's interest payments on its debt are well covered by EBIT (17.9x coverage).
Discover healthy companies
What is Duopharma Biotech Berhad current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DPHARMA's dividend (1.92%) isn’t notable compared to the bottom 25% of dividend payers in the MY market (2.15%).
High Dividend: DPHARMA's dividend (1.92%) is low compared to the top 25% of dividend payers in the MY market (4.94%).
Stability and Growth of Payments
Stable Dividend: DPHARMA's dividend payments have been volatile in the past 10 years.
Growing Dividend: DPHARMA's dividend payments have fallen over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (29.5%), DPHARMA's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: DPHARMA is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Leonard bin Abdul Shatar (56 yo)
Encik Ariff bin Abdul Shatar, also known as Leonard, has been Group Managing Director of Duopharma Biotech Berhad (alternate name Duopharma Biotech Bhd) since December 28, 2017. Encik bin Abdul Shatar serv...
CEO Compensation Analysis
Compensation vs Market: Leonard's total compensation ($USD517.62K) is above average for companies of similar size in the MY market ($USD169.79K).
Compensation vs Earnings: Leonard's compensation has increased by more than 20% in the past year.
Experienced Management: DPHARMA's management team is considered experienced (4.5 years average tenure).
Experienced Board: DPHARMA's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Duopharma Biotech Berhad's employee growth, exchange listings and data sources
- Name: Duopharma Biotech Berhad
- Ticker: DPHARMA
- Exchange: KLSE
- Founded: 1978
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: RM1.067b
- Shares outstanding: 952.24m
- Website: https://duopharmabiotech.com
Number of Employees
- Duopharma Biotech Berhad
- Kenanga International
- Suite 18.06, Level 18
- Kuala Lumpur
- Wilayah Persekutuan
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.